Literature DB >> 26085742

Maternal Anti-Ro/SSA and Anti-La/SSB Antibodies and Fetal Congenital Heart Block.

Anupam Kapur1, Madhusudan Dey1, Manoj Tangri2, H C Bandhu2.   

Abstract

Entities:  

Year:  2014        PMID： 26085742      PMCID： PMC4464570          DOI： 10.1007/s13224-014-0608-2

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN： 0975-6434


× No keyword cloud information.
  9 in total

1.  Classification of congenital complete heart block: autoantibody-associated or isolated?

Authors:  E Rosenthal
Journal:  Lupus       Date:  2003       Impact factor: 2.911

Review 2.  Fetal heart block associated with maternal anti-Ro (SS-A) antibody--current management. A review.

Authors:  K S Oláh; H Gee
Journal:  Br J Obstet Gynaecol       Date:  1991-08

3.  Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study.

Authors:  A Brucato; A Doria; M Frassi; G Castellino; F Franceschini; D Faden; M Pia Pisoni; L Solerte; M Muscarà; A Lojacono; M Motta; I Cavazzana; A Ghirardello; F Vescovi; V Tombini; R Cimaz; P F Gambari; P L Meroni; B Canesi; A Tincani
Journal:  Lupus       Date:  2002       Impact factor: 2.911

4.  Perinatal outcome of fetus with isolated congenital second degree atrioventricular block without maternal anti-SSA/Ro-SSB/La antibodies.

Authors:  Yao-Lung Chang; Peter C C Hsieh; Shuenn-Dyh Chang; An-Shine Chao; Ching Chung Liang; Yung-Kuei Soong
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2005-10-01       Impact factor: 2.435

5.  Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial.

Authors:  Deborah M Friedman; Carolina Llanos; Peter M Izmirly; Brigit Brock; John Byron; Joshua Copel; Karen Cummiskey; Mary Anne Dooley; Jill Foley; Cornelia Graves; Colleen Hendershott; Richard Kates; Elena V Komissarova; Michelle Miller; Emmanuelle Paré; Colin K L Phoon; Tracy Prosen; Dale Reisner; Eric Ruderman; Philip Samuels; Jerry K Yu; Mimi Y Kim; Jill P Buyon
Journal:  Arthritis Rheum       Date:  2010-04

6.  Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block.

Authors:  N Costedoat-Chalumeau; Z Amoura; D Le Thi Hong; B Wechsler; D Vauthier; P Ghillani; T Papo; O Fain; L Musset; J-C Piette
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

7.  Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry.

Authors:  J P Buyon; R Hiebert; J Copel; J Craft; D Friedman; M Katholi; L A Lee; T T Provost; M Reichlin; L Rider; A Rupel; S Saleeb; W L Weston; M L Skovron
Journal:  J Am Coll Cardiol       Date:  1998-06       Impact factor: 24.094

8.  Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block.

Authors:  Lynne E Nield; Earl D Silverman; Jeffrey F Smallhorn; Glenn P Taylor; J Brendan M Mullen; Leland N Benson; Lisa K Hornberger
Journal:  J Am Coll Cardiol       Date:  2002-08-21       Impact factor: 24.094

9.  Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study.

Authors:  Deborah M Friedman; Mimi Y Kim; Joshua A Copel; Claudine Davis; Colin K L Phoon; Julie S Glickstein; Jill P Buyon
Journal:  Circulation       Date:  2008-01-14       Impact factor: 29.690
  9 in total
  1 in total

1.  Hypergammaglobulinemic Purpura of Waldenstrom (HGPW) in Pregnancy: A Rare Case Report.

Authors:  Renuka Malik; Avani Goyal; Veena Ganju; Kabir Sardana
Journal:  J Obstet Gynaecol India       Date:  2018-06-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.